ArticleBMC pulmonary medicine2026
Elevated MMP2 expression in fibrotic interstitial lung disease: a potential biomarker for assessment of disease severity.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational Repurposing of FDA-Approved Drugs as Candidate MMP2 Inhibitors with Putative MMP3 Cross-Activity.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study was implemented to reveal the expression and the clinical correlation of matrix metalloproteinase 2 (MMP2) in patients with interstitial lung disease ILD. PATIENTS AND
methodsThis clinical study was conducted with 72 subjects (37 males, 35 females; mean age: 61.18(±13.95)years). They were divided into fibrotic group and non-fibrotic group based on whether the images showed fibrotic ILD. MMP2 concentrations in patients’ serum and bronchoalveolar lavage fluid balf were detected by enzyme-linked immunosorbent assay. Immunofluorescence staining was used to assess spatial expression of MMP2 and denatured collagen in fibrotic lung tissues.
resultsSerum and alveolar lavage fluid concentrations of MMP2 were significantly higher in the fibrosis group than in the non-fibrosis group. MMP2 level in serum was negatively correlated with forced expiratory volume in the first second (FEV1), total lung volume (TLC), residual volume (RV), and lung diffusing capacity for carbon monoxide (DLCO). Pearson statistical analysis revealed that MMP2 expression was positively related to leucocyte, carbohydrate antigen125 (CA125) and carcinoembryonic antigen(CEA). Fluorescently labeled collagen hybridizing peptide CHP was used to specifically localize degenerative collagen in the lung tissues of five lung transplantation patients, immunofluorescence results showed that MMP2 and CHP were co-localized and highly expressed in fibrosis tissue.
conclusionExpressions of MMP2 is significantly increased in patients with fibrotic interstitial lung disease. Higher expression of MMP2 implies more severe impairment of lung function, suggests that MMP2 could be used as potential biomarker for assessing severity of ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.